share_log

恒瑞医药:子公司注射用瑞康曲妥珠单抗纳入拟突破性治疗品种公示名单

Jiangsu Hengrui Pharmaceuticals: A subsidiary's injectable rituximab has been included in the list of proposed breakthrough therapies.

Breakings ·  Mar 19 09:01

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Suzhou Shengdiya Biomedical Co., Ltd.'s injectable Rukang Qutub monoclonal antibody has been included in the list of proposed breakthrough therapies by the National Medical Products Administration's Drug Review Center, with the intended indication for use in patients with recurrent or metastatic cervical cancer expressing HER2 (IHC≥1+) who have failed previous treatment with platinum-based chemotherapy and immune checkpoint inhibitors. This product has been included in the proposed breakthrough therapy list for the 8th time.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 269

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.